Genetic and adverse health outcome associations with treatment resistant hypertension in GenHAT

International Journal of Hypertension

Volumn 2013, Issue , 2013, Pages

  Lynch, Amy I ^a   Irvin, Marguerite R ^a   Davis, Barry R ^b   Ford, Charles E ^b   Eckfeldt, John H ^c   Arnett, Donna K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADDUCIN; ALPHA2 INTEGRIN; AMLODIPINE; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; APOLIPOPROTEIN B; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR; BETA3 INTEGRIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; CHLORTALIDONE; CLONIDINE; CYSTATHIONINE BETA SYNTHASE; DIPEPTIDYL CARBOXYPEPTIDASE; DOXAZOSIN; FIBRINOGEN; G PROTEIN COUPLED RECEPTOR KINASE 4; GLYCOPROTEIN IB; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; HYDRALAZINE; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN LIPASE; LISINOPRIL; PROTHROMBIN; RESERPINE; UNINDEXED DRUG;

ADULT; AGT GENE; ALLELE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA ISOLATION; DRUG DOSE TITRATION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; RISK ASSESSMENT;

EID: 84888861305     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2013/578578     Document Type: Article

References (39)

1. Egan B. M., Zhao Y., Axon R. N., Brzezinski W. A., Ferdinand K. C., Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011 124 9 1046 1058 2-s2.0-80052293937 10.1161/CIRCULATIONAHA.111.030189
2. Calhoun D. A., Jones D., Textor S., Goff D. C., Murphy T. P., Toto R. D., White A., Cushman W. C., White W., Sica D., Ferdinand K., Giles T. D., Falkner B., Carey R. M., Resistant hypertension: siagnosis, evaluation, and treatment a scientific statement from the american heart association professional education committee of the council for high blood pressure research. Hypertension 2008 51 6 1403 1419 2-s2.0-49249106417 10.1161/HYPERTENSIONAHA.108.189141
3. Gosain P., Garimella P. S., Hart P. D., Agarwal R., Renal sympathetic denervation for treatment of resistant hypertension: a systematic review. The Journal of Clinical Hypertension 2013 15 1 75 84 10.1111/jch.12027
4. Pimenta E., Calhoun D. A., Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012 125 13 1594 1596 2-s2.0-84859430725 10.1161/CIRCULATIONAHA.112.097345
5. Persell S. D., Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011 57 6 1076 1080 2-s2.0-79956370902 10.1161/HYPERTENSIONAHA.111.170308
6. Redmond N., Baer H. J., Hicks L. S., Health behaviors and racial disparity in blood pressure control in the national health and nutrition examination survey. Hypertension 2011 57 3 383 389 2-s2.0-79953253692 10.1161/HYPERTENSIONAHA.110.161950
7. Hannila-Handelberg T., Kontula K., Tikkanen I., Tikkanen T., Fyhrquist F., Helin K., Fodstad H., Piippo K., Meittinen H. E., Virtamo J., Krusius T., Sarna S., Gautschi I., Schild L., Hiltunen T. P., Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension. BMC Medical Genetics 2005 6, article 4 2-s2.0-26444449603 10.1186/1471-2350-6-4 (Pubitemid 41418165)
8. Ho H., Pinto A., Hall S. D., Flockhart D. A., Li L., Skaar T. C., Cadman P., O'Connor D. T., Wagner U., Fineberg N. S., Weinberger M. H., Association between the CYP3A5 genotype and blood pressure. Hypertension 2005 45 2 294 298 2-s2.0-19944431766 10.1161/01.HYP.0000151361.31736.96 (Pubitemid 40179975)
9. Yugar-Toledo J. C., Martin J. F. V., Krieger J. E., Pereira A. C., Demacq C., Coelho O. R., Pimenta E., Calhoun D. A., Moreno H. M. Jr., Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA and Cell Biology 2011 30 8 555 564 2-s2.0-79960935778 10.1089/dna.2010.1156
10. Xi B., Shen Y., Yan Y., Mi J., Association of polymorphisms in the AGT gene with essential hypertension in the Chinese population. Journal of Renin-Angiotensin-Aldosterone System 13 2 282 288 10.1177/1470320311430991
11. Winkelmann B. R., Russ A. P., Nauck M., Klein B., Bohm B. O., Maier V., Zotz R., Matheis G., Wolf A., Wieland H., Gross W., Galton D. J., Marz W., Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. American Heart Journal 1999 137 4, part 1 698 705 2-s2.0-0032915912 (Pubitemid 29173585)
12. Davis B. R., Cutler J. A., Gordon D. J., Furberg C. D., Wright J. T. Jr., Cushman W. C., Grimm R. H., LaRosa J., Whelton P. K., Perry H. M., Alderman M. H., Ford C. E., Oparil S., Francis C., Proschan M., Pressel S., Black H. R., Hawkins C. M., Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). American Journal of Hypertension 1996 9 4 342 360 2-s2.0-0029918188 10.1016/0895-7061(96)00037-4 (Pubitemid 26128245)
13. Arnett D. K., Boerwinkle E., Davis B. R., Eckfeldt J., Ford C. E., Black H., Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics Journal 2002 2 5 309 317 2-s2.0-0036448441 10.1038/sj.tpj. 6500113 (Pubitemid 35439473)
14. Lamina C., Digging into the extremes: a useful approach for the analysis of rare variants with continuous traits? BMC Proceedings 2011 5 supplement 9, article S105 2-s2.0-82455170369 10.1186/1753-6561-5-S9-S105
15. Marian A. J., Belmont J., Strategic approaches to unraveling genetic causes of cardiovascular diseases. Circulation Research 2011 108 10 1252 1269 2-s2.0-79957506175 10.1161/CIRCRESAHA.110.236067
16. Cushman W. C., Ford C. E., Cutler J. A., Margolis K. L., Davis B. R., Grimm R. H., Black H. R., Hamilton B. P., Holland J., Nwachuku C., Papademetriou V., Probstfield J., Wright J. T. Jr., Alderman M. H., Weiss R. J., Piller L., Bettencourt J., Walsh S. M., Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attact trial (ALLHAT). Journal of Clinical Hypertension 2002 4 6 393 404 2-s2.0-0036863587 (Pubitemid 35469393)
17. Einhorn P. T., Davis B. R., Massie B. M., Cushman W. C., Piller L. B., Simpson L. M., Levy D., Nwachuku C. E., Black H. R., The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure validation study: diagnosis and prognosis. American Heart Journal 2007 153 1 42 53 2-s2.0-33845467038 10.1016/j.ahj.2006.10.012 (Pubitemid 44895532)
18. Piller L. B., Davis B. R., Cutler J. A., Cushman W. C., Wright J. T. Jr., Williamson J. D., Leenen F. H. H., Einhorn P. T., Randall O. S., Golden J. S., Haywood L. J., Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone. Current Controlled Trials in Cardiovascular Medicine 2002 3, article 10 2-s2.0-27544436931 10.1186/1468-6708-3-10 (Pubitemid 41535285)
19. Cheng S., Grow M. A., Pallaud C., Klitz W., Erlich H. A., Visvikis S., Chen J. J., Pullinger C. R., Malloy M. J., Siest G., Kane J. P., A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Research 1999 9 10 936 949 2-s2.0-0032696776 10.1101/gr.9.10.936 (Pubitemid 29525202)
20. Yugar-Toledo J. C., Martin J. F. V., Krieger J. E., Pereira A. C., Demacq C., Coelho O. R., Pimenta E., Calhoun D. A., Moreno H. M. Jr., Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA and Cell Biology 2011 30 8 555 564 2-s2.0-79960935778 10.1089/dna.2010.1156
21. Li Y. Y., Lack of association of A-6G polymorphism of AGT gene with essential hypertension in the Chinese population. Journal of Cardiovascular Medicine 13 8 505 510 10.2459/JCM.0b013e328355a726
22. Mohana V. U., Swapna N., Surender R. S., Vishnupriya S., Padma T., Gender-related association of AGT gene variants (M235T and T174M) with essential hypertension-a case-control study. Clinical and Experimental Hypertension 2012 34 1 38 44 2-s2.0-84856649177 10.3109/10641963.2011.618207
23. Lightwood J., Fleischmann K. E., Glantz S. A., Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Journal of the American College of Cardiology 2001 37 6 1536 1542 2-s2.0-0035031970 10.1016/S0735-1097(01)01186-X (Pubitemid 32385986)
24. Buraczyńska M., Pijanowski Z., Spasiewicz D., Nowicka T., Sodolski T., Widomska-Czekajska T., Ksizek A., Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease. Kardiologia Polska 2003 58 1 1 9 2-s2.0-0037277016
25. Sethi A. A., Nordestgaard B. G., Grønholdt M.-L. M., Steffensen R., Jensen G., Tybjærg-Hansen A., Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease. Hypertension 2003 41 6 1202 1211 2-s2.0-0038796602 10.1161/01.HYP.0000072334. 34433.17 (Pubitemid 36706066)
26. Mondry A., Loh M., Liu P., Zhu A.-L., Nagel M., Polymorphisms of the insertion/deletion ACE and M235T AGT genes and hypertension: surprising new findings and meta-analysis of data. BMC Nephrology 2005 6, article 1 2-s2.0-14644404384 10.1186/1471-2369-6-1 (Pubitemid 40317991)
27. Calhoun D. A., Hyperaldosteronism as a common cause of resistant hypertension. Annual Review of Medicine 2013 64 233 247 10.1146/annurev-med- 042711-135929
28. Pimenta E., Gaddam K. K., Oparil S., Mechanisms and treatment of resistant hypertension. Journal of Clinical Hypertension 2008 10 3 239 244 2-s2.0-43549105386 10.1111/j.1751-7176.2008.08143.x
29. Sherva R., Ford C. E., Eckfeldt J. H., Davis B. R., Boerwinkle E., Arnett D. K., Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the Genetics of Hypertension Associated Treatment study. Stroke 2011 42 2 330 335 2-s2.0-79251645706 10.1161/STROKEAHA.110.593798
30. Ye S., Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovascular Research 2006 69 3 636 645 2-s2.0-31344438587 10.1016/j.cardiores.2005.07.015 (Pubitemid 43139726)
31. Taylor J., Sun Y. V., Chu J., Mosley T. H., Kardia S. L., Interactions between metallopeptidase 3 polymorphism rs679620 and BMI in predicting blood pressure in African-American women with hypertension. Journal of Hypertension 2008 26 12 2312 2318 2-s2.0-59849093125 10.1097/HJH.0b013e3283110402
32. Friese R. S., Rao F., Khandrika S., Thomas B., Ziegler M. G., Schmid-Schnbein G. W., O'Connor D. T., Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clinical and Experimental Hypertension 2009 31 7 521 533 2-s2.0-70449378212 10.3109/10641960802668730
33. Vilcek J., Lee T. H., Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. Journal of Biological Chemistry 1991 266 12 7313 7316 2-s2.0-0025779160 (Pubitemid 21906368)
34. Cheng J.-L., Wang A.-L., Wan J., Association between the M235T polymorphism of the AGT gene and cytokines in patients with hypertension. Experimental and Therapeutic Medicine 2012 3 3 509 512 2-s2.0-84855842013 10.3892/etm.2011.433
35. Bautista L. E., Vera L. M., Arenas I. A., Gamarra G., Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF- α) and essential hypertension. Journal of Human Hypertension 2005 19 2 149 154 2-s2.0-13544259939 10.1038/sj.jhh.1001785 (Pubitemid 40220638)
36. Zera T., Ufnal M., Szczepanska-Sadowska E., Central TNF- α elevates blood pressure and sensitizes to central pressor action of angiotensin II in the infarcted rats. Journal of Physiology and Pharmacology 2008 59 supplement 8 117 121 2-s2.0-63649109274
37. Carvajal C. A., Herrada A. A., Castillo C. R., Contreras F. J., Stehr C. B., Mosso L. M., Kalergis A. M., Fardella C. E., Primary aldosteronism can alter peripheral levels of transforming growth factor β and tumor necrosis factor α Journal of Endocrinological Investigation 2009 32 9 759 765 2-s2.0-74949136547 10.3275/6429
38. Lee S.-J., Kim W.-J., Moon S.-K., TNF- α regulates vascular smooth muscle cell responses in genetic hypertension. International Immunopharmacology 2009 9 7-8 837 843 2-s2.0-67349104194 10.1016/j.intimp.2009.03.010
39. Johnson A. D., Handsaker R. E., Pulit S. L., Nizzari M. M., O'Donnell C. J., de Bakker P. I. W., SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008 24 24 2938 2939 2-s2.0-57249114505 10.1093/bioinformatics/btn564